Literature DB >> 17999026

Adenosine: trigger and mediator of cardioprotection.

Michael V Cohen1, James M Downey.   

Abstract

Adenosine, a purine nucleoside, is ubiquitous in the body, and is a critical component of ATP. Its concentration jumps 100-fold during periods of oxygen depletion and ischemia. There are four adenosine receptors: A(1) and A(3) coupled to G(i/o) and the high-affinity A(2A) and low-affinity A(2B) coupled to G(s). Adenosine is one of three autacoids released by ischemic tissue which are important triggers of ischemic preconditioning (IPC). It is the A(1) and to some extent A(3) receptors which participate in the intracellular signaling that triggers cardioprotection. Unlike bradykinin and opioids, the other two autacoids, adenosine is not dependent on opening of mitochondrial K(ATP) channels or release of reactive oxygen species (ROS), but rather activates phospholipase C and/or protein kinase C (PKC) directly. Another signaling cascade at reperfusion involves activated PKC which initiates binding to and activation of an A(2) adenosine receptor that we believe is the A(2B). Although the latter is the low-affinity receptor, its interaction with PKC increases its affinity and makes it responsive to the accumulated tissue adenosine. A(2B) agonists, but not adenosine or A(1) agonists, infused at reperfusion can initiate this second signaling cascade and mimic preconditioning's protection. The same A(2B) receptors are critical for postconditioning's protection. Thus adenosine is both an important trigger and a mediator of cardioprotection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999026     DOI: 10.1007/s00395-007-0687-7

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  56 in total

1.  Factors mediating remote preconditioning of trauma in the rat heart: central role of the cytochrome p450 epoxygenase pathway in mediating infarct size reduction.

Authors:  Garrett J Gross; Anna Hsu; Eric R Gross; John R Falck; Kasem Nithipatikom
Journal:  J Cardiovasc Pharmacol Ther       Date:  2012-03-09       Impact factor: 2.457

Review 2.  Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.

Authors:  Louise E See Hoe; Lauren T May; John P Headrick; Jason N Peart
Journal:  Br J Pharmacol       Date:  2016-09-09       Impact factor: 8.739

Review 3.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

Review 4.  Adenosine receptors and the kidney.

Authors:  Volker Vallon; Hartmut Osswald
Journal:  Handb Exp Pharmacol       Date:  2009

Review 5.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

Review 6.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

Review 7.  Autophagy, myocardial protection, and the metabolic syndrome.

Authors:  Zoltan Giricz; Robert M Mentzer; Roberta A Gottlieb
Journal:  J Cardiovasc Pharmacol       Date:  2012-08       Impact factor: 3.105

8.  PHLPP-1 negatively regulates Akt activity and survival in the heart.

Authors:  Shigeki Miyamoto; Nicole H Purcell; Jeffrey M Smith; Tianyan Gao; Ross Whittaker; Katherine Huang; Rene Castillo; Chris C Glembotski; Mark A Sussman; Alexandra C Newton; Joan Heller Brown
Journal:  Circ Res       Date:  2010-06-24       Impact factor: 17.367

9.  Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions.

Authors:  L T May; S J Briddon; S J Hill
Journal:  Mol Pharmacol       Date:  2010-01-19       Impact factor: 4.436

10.  Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog.

Authors:  Garrett J Gross; Kathryn M Gauthier; Jeannine Moore; William B Campbell; John R Falck; Kasem Nithipatikom
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-15       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.